Revvity, Inc. (RVTY) recently announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with its T-SPOT.TB test. The solution, which has an intuitive software user interface, is expected to simplify lab workflows.The latest product is expected to significantly boost Revvity’s Diagnostics segment and solidify its foothold in the infectious diseases space.Significance of the LaunchPer Revvity, the easy-to-use Auto-Pure 2400 platform has been designed to provide efficient workflows in the ...

Revvity, Inc. (RVTY) recently announced that its software and informatics division, Revvity Signals, will launch Signals Synergy. Per the company, it is a software solution designed to drive greater collaboration, project management and data exchange between pharmaceutical and biotechnology sponsors with their external contract partners.Revvity is expected to officially introduce Signals Synergy at the ongoing Bio-IT World Conference & Expo in Boston, MA.The latest product is expected to significantly boost ...

Revvity (RVTY) shares rallied 4.1% in the last trading session to close at $110.72. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.6% loss over the past four weeks.The prices are likely to have moved higher in anticipation of positive first quarter results, scheduled to be announced on Apr 29.This maker of scientific instruments is expected to post quarterly earnings of $0.94 per share in its upcoming repo ...

Revvity, Inc. (RVTY) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by its fourth-quarter 2023 and its focus on artificial intelligence (AI) also looks promising. Headwinds resulting from foreign exchange volatility and integration risks are major downsides.Over the past year, this Zacks Rank #3 (Hold) stock has lost 21.2% against the 6% rise of the industry and 27.7% growth of the S&P 500.The renowned provider of health science solutions has a m ...

Revvity, Inc. (RVTY) recently introduced the new Signals ChemDraw offering through its software and informatics division, Revvity Signals Software. The innovative chemistry suite is expected to transform the way researchers in the pharmaceutical and non-pharmaceutical chemical industries, and academia develop and communicate complex chemical concepts and collaborate across disciplines.The latest product is expected to significantly boost Revvity’s Signals Software portfolio on a global scale and solidify it ...

Revvity, Inc. (RVTY) recently announced the introduction of a flexible end-to-end workflow solution for newborn research. This will likely enable the users to utilize different instruments, reagents and databases based on a lab’s requirements.The research-use-only offering includes dried blood spot collection and processing devices, Chemagic kits and instruments for nucleic acid extraction, liquid handlers and reagents for library preparation, VICTOR2 D Instrument for sample quality control and software cap ...

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals Software, is introducing the new Signals ChemDraw® offering, the latest advancement in the Revvity Signals Software portfolio. This innovative chemistry suite is set to transform the way researchers in the pharmaceutical and non-pharmaceutical chemical industries, as well as academia, develop and communicate complex chemical concepts and collaborate across disciplines. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 940 Winter Street, Waltham, Massachusetts 02451 (Address of Principal Executive Of ices) (Zip Code) (781) 663-6900 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced it will present at the following investor conferences in February and March 2024: Citi's 2024 Unplugged MedTech and Life Sciences Access Day - New York City, NY Thursday, February 29, 2024 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 44th Annual Health Care Conference – Boston, MA Monday, March 4, 2024 9:10 a.m. ET - Prahlad Singh, president and chief executive officer Raymond James 45t ...

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals, is unveiling the Signals ClinicalTM solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable insights for quicker clinical decisions and accelerated market delivery of therapeutics. This state-of-the-art solution, when integrated with enterprise-class Spotfire visual anal ...